PMID- 35734398
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular 
      Carcinoma.
PG  - 917384
LID - 10.3389/fphar.2022.917384 [doi]
LID - 917384
AB  - Background: The RESORCE trial reported that regorafenib was effective as the 
      second-line treatment for patients with hepatocellular carcinoma (HCC) after 
      progression on sorafenib. Real-world data are needed to assess clinical outcomes 
      and adverse events in the setting of daily practice. Objective: We aimed to 
      evaluate the efficacy and safety of regorafenib after disease progression with 
      sorafenib in Chinese patients with advanced HCC. Patients and Methods: A total of 
      41 patients with advanced HCC who did not respond to sorafenib and followed a 
      regorafenib regimen were enrolled in this retrospective study. Overall survival 
      (OS), progression-free survival (PFS), radiological responses, and adverse events 
      (AEs) were evaluated. Survival curves were compared by using the log-rank test 
      and constructed with the Kaplan-Meier method. Results: The median PFS with 
      regorafenib was 6.6 months (range: 5.0-8.2 months), and the median OS with 
      regorafenib was not reached. The 1-year OS rate of regorafenib was 66.4%. The 
      median OS of sequential sorafenib to regorafenib treatment was 35.3 months [95% 
      confidence interval (CI), 24.3-46.3], and the 2-year OS rate of sequential 
      sorafenib to regorafenib treatment was 74.4%. The most common AEs of regorafenib 
      treatment were elevated aspartate aminotransferase [17/41 patients (41.5%)], 
      elevated alanine aminotransferase [16/41 patients (39%)] and hand-foot syndrome 
      [14/41 patients (34.1%)]. Conclusion: Regorafenib appears to be safe and 
      clinically effective in patients with advanced HCC who progressed on first-line 
      sorafenib.
CI  - Copyright (c) 2022 Hou, Xiao, Huang, Jiang, Jiang, Li, Xu and Chen.
FAU - Hou, Jing-Yu
AU  - Hou JY
AD  - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Guangzhou, China.
FAU - Xiao, Ya-Ting
AU  - Xiao YT
AD  - School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, 
      Hangzhou, China.
FAU - Huang, Jing-Bo
AU  - Huang JB
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hunan 
      Normal University (Hunan Provincial People's Hospital), Changsha, China.
FAU - Jiang, Xin-Hua
AU  - Jiang XH
AD  - Department of Radiology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Jiang, Kai
AU  - Jiang K
AD  - Department of Orthopaedics, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Li, Xun
AU  - Li X
AD  - School of Chemical Engineering, University of Chinese Academy of Sciences, 
      Beijing, China.
FAU - Xu, Li
AU  - Xu L
AD  - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Guangzhou, China.
FAU - Chen, Min-Shan
AU  - Chen MS
AD  - Department of Liver Surgery, Sun Yat-sen University Cancer Center, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220606
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9207200
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - prognosis
OT  - regorafenib
OT  - retrospective study
OT  - sorafenib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/24 06:00
MHDA- 2022/06/24 06:01
PMCR- 2022/06/06
CRDT- 2022/06/23 02:41
PHST- 2022/04/11 00:00 [received]
PHST- 2022/05/16 00:00 [accepted]
PHST- 2022/06/23 02:41 [entrez]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/06/24 06:01 [medline]
PHST- 2022/06/06 00:00 [pmc-release]
AID - 917384 [pii]
AID - 10.3389/fphar.2022.917384 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jun 6;13:917384. doi: 10.3389/fphar.2022.917384. 
      eCollection 2022.